COVID‐19 vaccine: recent advancements and future prospects

Author:

Xu Li1ORCID,Li Min1,He Wu1

Affiliation:

1. Center for Drug Evaluation National Medical Products Administration Beijing China

Abstract

AbstractNowadays, although severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) epidemic has been handled with long‐term management globally, the virus strains keep continuous evolution in an uncertain direction. The newly emerged JN.1 dominated the globally circulating variants in a short time and resulted in increasing hospitalizations. Up to 2024, variant vaccines with the composition of XBB sub‐lineage were available due to the coordinated efforts of developers and regulatory agencies. The development of updated vaccines is still needed and the regular availability of coronavirus disease 2019 (COVID‐19) vaccines should be timely guaranteed. The current landscape of COVID‐19 vaccines and the strategies for accelerating vaccine development and approval are reviewed. Proposals to enhance variants monitoring and the establishment of the strain recommendation mechanism are made. This review provides suggestions about platform technology designation and application, real‐world data leveraging and modification to regulatory pathways both for the post‐pandemic era of SARS‐CoV‐2 and for the future unknown pathogen pandemic.

Publisher

Wiley

Reference43 articles.

1. WHO Director‐General's Opening Remarks at the Media Briefing. May 5 2023.World Health Organization. Updated May 5 2023.https://www.who.int/zh/director‐general/speeches/detail/who‐director‐general‐s‐opening‐remarks‐at‐the‐media‐briefing—5‐may‐2023

2. Tracking SARS‐CoV‐2 Variants.World Health Organization. Updated February 16 2024.https://www.who.int/activities/tracking‐SARS‐CoV‐2‐variants/

3. Are repeat COVID infections dangerous? What the science says

4. COVID’s future: mini-waves rather than seasonal surges

5. Moderna COVID‐19 Vaccine (2023‒2024 Formula) Authorized For Individuals 6 Months through 11 Years of Age.U.S. Food and Drug Administration. Updated November 1 2023.https://www.fda.gov/vaccines‐blood‐biologics/coronavirus‐covid‐19‐cber‐regulated‐biologics/moderna‐covid‐19‐vaccine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3